With fresh company building lessons from Ablynx, Edwin Moses is ready to try it again as chair of neoantigen biotech Achilles
After officially passing off Ablynx to Sanofi in July, Edwin Moses took August off — the longest break the biotech CEO has had in about 20 years.
“By the end of that I was already bored,” he says.
At the recommendation of longtime friend and Syncona CEO Martin Murphy, Moses has taken his first role since sealing the $4.8 billion acquisition deal about 10 months ago: board chairman at Achilles Therapeutics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
